Payment overview · 2025
General Payments
$1,235.56
69 reported records · 16 companies
Healthcare provider profile · identity verified
Matthew L. Nettleton, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BLAIRSVILLE, PA · NPI 1114983616
Verified facts
What the public records show
CMS Open Payments records show Matthew L. Nettleton, MD received $1,235.56 in general payments during 2025 across 69 reported records.
ABBVIE INC. accounted for 30.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 427 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 427 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 406 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $381.27 | 30.9% | 32 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $214.17 | 17.3% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $135.34 | 10.9% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $94.13 | 7.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $77.51 | 6.3% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $71.03 | 5.8% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.51 | 3.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $46.37 | 3.8% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $36.64 | 3.0% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $33.79 | 2.7% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.76 | 1.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.15 | 1.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.25 | 1.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.84 | 1.2% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.63 | 1.2% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $14.17 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,235.56 | 69 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $334.11 | 27 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $291.14 | 23 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $214.17 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $135.34 | 7 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $94.13 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $77.51 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $71.03 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $58.61 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $54.54 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $47.51 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $47.51 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $47.16 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $46.37 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $36.64 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $33.79 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| ONZETRA XSAIL Normalized: onzetra xsail |
Drug | Currax Pharmaceuticals LLC | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $14.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 52 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 427 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
40 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
84 | 25 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
108 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
52 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
427 | 53 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
427 | 53 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
130 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
406 | 64 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1121 | 263 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1067 | 200 |
| Pantoprazole Sodium | Pantoprazole Sodium | 712 | 166 |
| Amlodipine Besylate | Amlodipine Besylate | 677 | 167 |
| Furosemide | Furosemide | 611 | 106 |
| Lisinopril | Lisinopril | 447 | 105 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 433 | 101 |
| Potassium Chloride | Potassium Chloride | 429 | 85 |
| Jardiance | Empagliflozin | 427 | 53 |
| Losartan Potassium | Losartan Potassium | 417 | 112 |
| Eliquis | Apixaban | 406 | 64 |
| Escitalopram Oxalate | Escitalopram Oxalate | 394 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 379 | 80 |
| Tamsulosin Hcl | Tamsulosin Hcl | 362 | 82 |
| Gabapentin | Gabapentin | 355 | 73 |
| Simvastatin | Simvastatin | 339 | 76 |
| Metformin Hcl | Metformin Hcl | 333 | 76 |
| Tramadol Hcl | Tramadol Hcl | 313 | 109 |
| Omeprazole | Omeprazole | 312 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 311 | 76 |
| Duloxetine Hcl | Duloxetine Hcl | 292 | 57 |
| Citalopram Hbr | Citalopram Hydrobromide | 253 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 251 | 58 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 243 | 56 |
| Xarelto | Rivaroxaban | 233 | 21 |
| Famotidine | Famotidine | 228 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 220 | 51 |
| Allopurinol | Allopurinol | 214 | 47 |
| Montelukast Sodium | Montelukast Sodium | 204 | 44 |
| Trazodone Hcl | Trazodone Hcl | 197 | 47 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 194 | 55 |
| Meloxicam | Meloxicam | 193 | 58 |
| Sertraline Hcl | Sertraline Hcl | 180 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 178 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 177 | 85 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 174 | 50 |
| Hydralazine Hcl | Hydralazine Hcl | 170 | 43 |
| Methylprednisolone | Methylprednisolone | 170 | 150 |
| Labetalol Hcl | Labetalol Hcl | 161 | 36 |
| Valsartan | Valsartan | 149 | 35 |
| Warfarin Sodium | Warfarin Sodium | 146 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 144 | 22 |
| Donepezil Hcl | Donepezil Hcl | 143 | 27 |
| Lorazepam | Lorazepam | 141 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 133 | 32 |
| Ozempic | Semaglutide | 130 | 28 |
| Tradjenta | Linagliptin | 127 | 19 |
| Glimepiride | Glimepiride | 125 | 30 |
| Buspirone Hcl | Buspirone Hcl | 124 | 29 |
| Finasteride | Finasteride | 113 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 112 | 53 |
| Alendronate Sodium | Alendronate Sodium | 110 | 26 |
| Myrbetriq | Mirabegron | 108 | 15 |
| Metformin Hcl Er | Metformin Hcl | 103 | 28 |
| Alprazolam | Alprazolam | 98 | 21 |
| Memantine Hcl | Memantine Hcl | 97 | 16 |
| Carvedilol | Carvedilol | 95 | 23 |
| Clonazepam | Clonazepam | 91 | 22 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 91 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 88 | 33 |
| Mirtazapine | Mirtazapine | 88 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 86 | 16 |
| Ezetimibe | Ezetimibe | 84 | 24 |
| Synthroid | Levothyroxine Sodium | 84 | 25 |
| Levetiracetam | Levetiracetam | 81 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 81 | 63 |
| Azithromycin | Azithromycin | 73 | 71 |
| Pioglitazone Hcl | Pioglitazone Hcl | 73 | 16 |
| Solifenacin Succinate | Solifenacin Succinate | 73 | 13 |
| Atenolol | Atenolol | 72 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 25 |
| Sucralfate | Sucralfate | 70 | 25 |
| Spironolactone | Spironolactone | 69 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 67 | 29 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 65 | 13 |
| Celecoxib | Celecoxib | 65 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 61 | 36 |
| Prednisone | Prednisone | 60 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 22 |
| Lamotrigine | Lamotrigine | 58 | 11 |
| Aripiprazole | Aripiprazole | 57 | 14 |
| Digoxin | Digoxin | 56 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 55 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 55 | 21 |
| Trulicity | Dulaglutide | 53 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 14 |
| Farxiga | Dapagliflozin Propanediol | 52 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 47 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 51 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | suppressed |
| Baclofen | Baclofen | 49 | 12 |
| Cefdinir | Cefdinir | 48 | 33 |
| Humalog | Insulin Lispro | 48 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 21 |
| Benazepril Hcl | Benazepril Hcl | 46 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 46 | suppressed |
| Fentanyl | Fentanyl | 46 | suppressed |
| Temazepam | Temazepam | 46 | 12 |
| Pregabalin | Pregabalin | 42 | 13 |
| Sevelamer Carbonate | Sevelamer Carbonate | 41 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | suppressed |
| Linzess | Linaclotide | 40 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Nystatin | Nystatin | 37 | 26 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Levofloxacin | Levofloxacin | 33 | 30 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 32 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Creon | Lipase/Protease/Amylase | 31 | suppressed |
| Latanoprost | Latanoprost | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Hydrocortisone | Hydrocortisone | 30 | 13 |
| Cephalexin | Cephalexin | 29 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 19 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 27 | suppressed |
| Ingrezza | Valbenazine Tosylate | 27 | suppressed |
| Metolazone | Metolazone | 27 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Insulin Lispro | Insulin Lispro | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Mirabegron Er | Mirabegron | 24 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | 11 |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 22 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 16 |
| Risedronate Sodium | Risedronate Sodium | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Calcium Acetate | Calcium Acetate | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Novolog | Insulin Aspart | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Calcitriol | Calcitriol | 18 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Tolterodine Tartrate | Tolterodine Tartrate | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 15 | 14 |
| Bethanechol Chloride | Bethanechol Chloride | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 15 |
| Jantoven | Warfarin Sodium | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Desoximetasone | Desoximetasone | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Oxycontin | Oxycodone Hcl | 14 | suppressed |
| Permethrin | Permethrin | 14 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 13 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Eplerenone | Eplerenone | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Mesalamine Dr | Mesalamine | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,235.56 · 69 records | ABBVIE INC. | CONTRAVE, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, Flexitouch Plus, IBSRELA, JARDIANCE, MOUNJARO, NURTEC ODT, Nimbl, ONZETRA XSAIL, OTEZLA, QULIPTA, REPATHA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error